A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses
about
An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.A cationic liposome-DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets.Inactivated influenza vaccines: recent progress and implications for the elderly.Poly-γ-glutamic acid/chitosan nanogel greatly enhances the efficacy and heterosubtypic cross-reactivity of H1N1 pandemic influenza vaccineImmunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccineInducing dose sparing with inactivated polio virus formulated in adjuvant CAF01.Pricing of new vaccines.Immunologic non-inferiority of a newly licensed inactivated trivalent influenza vaccine versus an established vaccine: a randomized study in US adults.An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques.Immunosenescence and Challenges of Vaccination against Influenza in the Aging Population.Transcriptomics and proteomics in the study of H1N1 2009.The virosomal adjuvanted influenza vaccine.A rational, systematic approach for the development of vaccine formulations.Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations.Improving immunogenicity and effectiveness of influenza vaccine in older adults.Safety and immunogenicity of the novel seasonal preservative- and adjuvant-free influenza vaccine: blind, randomized and placebo-controlled trial.Finding a new drug and vaccine for emerging swine flu: what is the concept?Evolution of Therapeutic Antibodies, Influenza Virus Biology, Influenza, and Influenza Immunotherapy.
P2860
Q30352329-4AA42429-2DE3-480D-95FE-79FB25A67CDDQ30385570-D0CB0AF0-C830-4C97-90AE-E1AC716094A3Q30399057-013554D6-0060-4758-9496-086A69B4798DQ30400146-D48BDF62-4AA6-4DD4-93B7-72C72F82E829Q30430552-6C5A01D7-CF0A-40C0-99B8-7C565280C347Q33793770-9F81C937-534B-4FE9-9AEF-BAA379D471C0Q34663970-282908B9-AA02-4F39-A70E-9BF3E7A96786Q34706925-112D52EB-0F15-4204-8BB6-5069E14E3140Q35272502-740083C3-6FEB-4C09-9976-625678016D32Q35874111-6EA37134-8C20-46CC-BB53-701E53DFB5A3Q37318402-4C4078AB-B672-4603-8D74-8C973DC8274FQ37678409-2785140E-1882-4FF9-8BAF-66010AAF8976Q37846559-BE0C7C31-EE75-4B5C-85EC-6E63D5A26122Q37857257-B54F646B-D1E4-4478-9DF4-BE7FFECB0E49Q37951523-BD8B4C37-F7DC-401B-8C90-46626EF6BAF1Q40069663-877801CC-DB07-4861-B2F8-9217AE5316F8Q40379215-B64CF50D-0647-474F-A83B-53DF172C92C1Q55554478-751EE98B-A93A-4AEA-9519-CC421526E687
P2860
A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
A vaccine manufacturer's appro ...... and pandemic influenza viruses
@ast
A vaccine manufacturer's appro ...... and pandemic influenza viruses
@en
type
label
A vaccine manufacturer's appro ...... and pandemic influenza viruses
@ast
A vaccine manufacturer's appro ...... and pandemic influenza viruses
@en
prefLabel
A vaccine manufacturer's appro ...... and pandemic influenza viruses
@ast
A vaccine manufacturer's appro ...... and pandemic influenza viruses
@en
P2093
P2860
P1476
A vaccine manufacturer's appro ...... and pandemic influenza viruses
@en
P2093
Benoit Baras
Emmanuel Hanon
Jeanne-Marie Devaster
Louis Fries
Nancy Bouveret
Paul Gillard
Roland Sänger
P2860
P304
P356
10.1111/J.1750-2659.2008.00054.X
P577
2008-11-01T00:00:00Z